Inconsistencies surrounding the risk of adverse outcomes with concomitant use of clopidogrel and proton pump inhibitors

Chun Shing Kwok, Yoon Kong Loke

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


There is considerable debate surrounding the clinical relevance of an adverse interaction between clopidogrel and proton pump inhibitors (PPIs). Some studies have indicated that PPIs may attenuate the antiplatelet efficacy of clopidogrel, thus leading to increased risk of thrombotic cardiovascular events.
Original languageEnglish
Pages (from-to)275-84
Number of pages10
JournalExpert Opinion on Drug Safety
Issue number2
Publication statusPublished - Mar 2012


  • Animals
  • Blood Platelets
  • Drug Interactions
  • Evidence-Based Medicine
  • Gastrointestinal Hemorrhage
  • Humans
  • Platelet Aggregation Inhibitors
  • Proton Pump Inhibitors
  • Risk Assessment
  • Risk Factors
  • Ticlopidine

Cite this